-
Mashup Score: 39Outcomes after biochemical or clinical progression in patients with multiple myeloma - PubMed - 11 day(s) ago
Almost all patients with multiple myeloma (MM) eventually relapse, either asymptomatically or with end-organ damage. However, it remains unclear whether initiating therapy at the time of biochemical progression (BP) improves the outcomes compared with initiating therapy at the clinical progression ( …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 39
Upfront autologous stem cell transplantation improves overall survival in patients with newly diagnosed myeloma harboring high-risk cytogenetics.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 37Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis - PubMed - 11 day(s) ago
Use of surrogate end-points such as progression-free survival (PFS) and other time-to-event (TTE) end-points is common in multiple myeloma (MM) clinical trials. This systematic review characterises all published randomised controlled trials (RCTs) in MM using PFS or other TTE end-points between 2005 …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 19Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma - BMC Cancer - 11 day(s) ago
Objectives The goal of the research was to assess the quantitative relationship between median progression-free survival (PFS) and median overall survival (OS) specifically among patients with relapsed/refractory multiple myeloma (RRMM) based on published randomized controlled trials (RCTs). Methods Two bibliographic databases (PubMed and Embase, 1970–2017) were systematically searched for RCTs in RRMM that reported OS and PFS, followed by an updated search of studies published between 2010 and 2022 in 3 databases (Embase, MEDLINE, and EBM Reviews, 2010–2022). The association between median PFS and median OS was assessed using the nonparametric Spearman rank and parametric Pearson correlation coefficients. Subsequently, the quantitative relationship between PFS and OS was assessed using weighted least-squares regression adjusted for covariates including age, sex, and publication year. Study arms were weighted by the number of patients in each arm. Results A total of 31 RCTs (56 treatme
Source: bmccancer.biomedcentral.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 20Closed Borders of our Empathy — Critical Forced Displacement - 16 day(s) ago
Dr. Alina Sadaf, MD recounts her experiences as a pediatric oncologist working with Afghan refugees in Lahore, Pakistan.
Categories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 2
Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant – Full Text View.
Source: classic.clinicaltrials.govCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1Dietary interventions in cancer: a systematic review of all randomized controlled trials - 19 day(s) ago
AbstractBackground. Prior systematic reviews addressing the impact of diet on cancer outcomes have focused on specific dietary interventions. In this systematic
Source: academic.oup.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1Dietary interventions in cancer: a systematic review of all randomized controlled trials - 22 day(s) ago
AbstractBackground. Prior systematic reviews addressing the impact of diet on cancer outcomes have focused on specific dietary interventions. In this systematic
Source: academic.oup.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 40
In this episode, Anthony and Bernie are joined by Multiple Myeloma expert Dr. Manni Mohyuddin, to discuss the recent FDA approval updates of CAR-T in this disease state. We also discuss the hotly debated topic of MRD as a surrogate endpoint for accelerated approval in Myeloma.
Source: podcasters.spotify.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 46
In March 1998, Common Toxicity Criteria (CTC) version 2.0 introduced the collection of attribution of adverse events (AEs) to study drug. We investigate whether attribution adds value to the interpretation of AE data.Patients in the placebo arm of two …
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, Partners & KOLsTweet
1) Most, but not all disease progressions at the time of relapse are biochemical (as in myeloma proteins increasing) and not clinical (as in new organ damage, anemia, bone lesions etc) https://t.co/5wddu39sGM